Literature DB >> 19188577

Executive dysfunction in frontotemporal dementia and corticobasal syndrome.

E D Huey1, E N Goveia, S Paviol, M Pardini, F Krueger, G Zamboni, M C Tierney, E M Wassermann, J Grafman.   

Abstract

OBJECTIVE: To determine the pattern of executive dysfunction in frontotemporal dementia (FTD) and corticobasal syndrome (CBS) and to determine the brain areas associated with executive dysfunction in these illnesses.
METHOD: We administered the Delis-Kaplan Executive Function System (D-KEFS), a collection of standardized executive function tests, to 51 patients with behavioral-variant FTD and 50 patients with CBS. We also performed a discriminant analysis on the D-KEFS to determine which executive function tests best distinguished the clinical diagnoses of FTD and CBS. Finally, we used voxel-based morphometry (VBM) to determine regional gray matter volume loss associated with executive dysfunction.
RESULTS: Patients with FTD and patients with CBS showed executive dysfunction greater than memory dysfunction. Executive function was better preserved in the patients with CBS than the patients with FTD with the exception of tests that required motor, visuospatial ability, or both. In patients with CBS, dorsal frontal and parietal and temporal-parietal cortex was associated with executive function. In FTD, tests with a language component (Verbal Fluency) were associated with left perisylvian cortex, sorting with the left dorsolateral prefrontal cortex, and reasoning (the Twenty Questions task) with the left anterior frontal cortex. The Twenty Questions test best distinguished the clinical diagnoses of CBS and FTD.
CONCLUSIONS: The neuroanatomic findings (especially in frontotemporal dementia [FTD]) agree with the previous literature on this topic. Patients with FTD and patients with corticobasal syndrome (CBS) show disparate performance on higher-order executive functions, especially the Twenty Questions test. It may be difficult to distinguish motor and visuospatial ability from executive function in patients with CBS using tests with significant motor and visuospatial demands such as Trail Making.

Entities:  

Mesh:

Year:  2009        PMID: 19188577      PMCID: PMC2677529          DOI: 10.1212/01.wnl.0000341781.39164.26

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Why voxel-based morphometry should be used.

Authors:  J Ashburner; K J Friston
Journal:  Neuroimage       Date:  2001-12       Impact factor: 6.556

2.  Thresholding of statistical maps in functional neuroimaging using the false discovery rate.

Authors:  Christopher R Genovese; Nicole A Lazar; Thomas Nichols
Journal:  Neuroimage       Date:  2002-04       Impact factor: 6.556

Review 3.  The prefrontal cortex: insights from functional neuroimaging using cognitive activation tasks.

Authors:  Ingeborg Goethals; Kurt Audenaert; Christophe Van de Wiele; Rudi Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-23       Impact factor: 9.236

4.  Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders.

Authors:  Irene Litvan; Kailash P Bhatia; David J Burn; Christopher G Goetz; Anthony E Lang; Ian McKeith; Niall Quinn; Kapil D Sethi; Cliff Shults; Gregor K Wenning
Journal:  Mov Disord       Date:  2003-05       Impact factor: 10.338

5.  Reliability and validity of the Delis-Kaplan Executive Function System: an update.

Authors:  Dean C Delis; Joel H Kramer; Edith Kaplan; James Holdnack
Journal:  J Int Neuropsychol Soc       Date:  2004-03       Impact factor: 2.892

Review 6.  Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

7.  Office of Rare Diseases neuropathologic criteria for corticobasal degeneration.

Authors:  D W Dickson; C Bergeron; S S Chin; C Duyckaerts; D Horoupian; K Ikeda; K Jellinger; P L Lantos; C F Lippa; S S Mirra; M Tabaton; J P Vonsattel; K Wakabayashi; I Litvan
Journal:  J Neuropathol Exp Neurol       Date:  2002-11       Impact factor: 3.685

8.  Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease?

Authors:  S Bozeat; C A Gregory; M A Ralph; J R Hodges
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

Review 9.  Neurocognitive profiles in elderly patients with frontotemporal degeneration or major depressive disorder.

Authors:  Virginia Elderkin-Thompson; Kyle B Boone; Sun Hwang; Anand Kumar
Journal:  J Int Neuropsychol Soc       Date:  2004-09       Impact factor: 2.892

10.  Is it bigger than a breadbox? Performance of patients with prefrontal lesions on a new executive function test.

Authors:  Juliana V Baldo; Dean C Delis; David P Wilkins; Arthur P Shimamura
Journal:  Arch Clin Neuropsychol       Date:  2004-04       Impact factor: 2.813

View more
  32 in total

1.  Gray matter correlates of set-shifting among neurodegenerative disease, mild cognitive impairment, and healthy older adults.

Authors:  Judy Pa; Katherine L Possin; Stephen M Wilson; Lovingly C Quitania; Joel H Kramer; Adam L Boxer; Michael W Weiner; Julene K Johnson
Journal:  J Int Neuropsychol Soc       Date:  2010-04-07       Impact factor: 2.892

2.  The role of the Met66 brain-derived neurotrophic factor allele in the recovery of executive functioning after combat-related traumatic brain injury.

Authors:  Frank Krueger; Matteo Pardini; Edward D Huey; Vanessa Raymont; Jeffrey Solomon; Robert H Lipsky; Colin A Hodgkinson; David Goldman; Jordan Grafman
Journal:  J Neurosci       Date:  2011-01-12       Impact factor: 6.167

Review 3.  The behavioral variant of frontotemporal dementia: linking neuropathology to social cognition.

Authors:  Chiara Cerami; Stefano F Cappa
Journal:  Neurol Sci       Date:  2013-02-03       Impact factor: 3.307

4.  Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome.

Authors:  Michele Poletti; Claudio Lucetti; Chiara Logi; Filippo Baldacci; Gabriele Cipriani; Angelo Nuti; Paolo Borelli; Ubaldo Bonuccelli
Journal:  Neurol Sci       Date:  2013-03-27       Impact factor: 3.307

5.  Individual differences in regional prefrontal gray matter morphometry and fractional anisotropy are associated with different constructs of executive function.

Authors:  H R Smolker; B E Depue; A E Reineberg; J M Orr; M T Banich
Journal:  Brain Struct Funct       Date:  2014-02-22       Impact factor: 3.270

6.  Frontotemporal dementia: clinical, neuropsychological, and neuroimaging description.

Authors:  Juan Carlos Rivas Nieto
Journal:  Colomb Med (Cali)       Date:  2014-09-30

7.  Double dissociation in the anatomy of socioemotional disinhibition and executive functioning in dementia.

Authors:  Casey E Krueger; Victor Laluz; Howard J Rosen; John M Neuhaus; Bruce L Miller; Joel H Kramer
Journal:  Neuropsychology       Date:  2011-03       Impact factor: 3.295

8.  Dementia induces correlated reductions in white matter integrity and cortical thickness: a multivariate neuroimaging study with sparse canonical correlation analysis.

Authors:  Brian B Avants; Philip A Cook; Lyle Ungar; James C Gee; Murray Grossman
Journal:  Neuroimage       Date:  2010-01-18       Impact factor: 6.556

Review 9.  Language, executive function and social cognition in the diagnosis of frontotemporal dementia syndromes.

Authors:  Michał Harciarek; Stephanie Cosentino
Journal:  Int Rev Psychiatry       Date:  2013-04

10.  Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease.

Authors:  Kwangsik Nho; Shannon L Risacher; Paul K Crane; Charles DeCarli; M Maria Glymour; Christian Habeck; Sungeun Kim; Grace J Lee; Elizabeth Mormino; Shubhabrata Mukherjee; Li Shen; John D West; Andrew J Saykin
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.